Copyright
©The Author(s) 2017.
World J Stem Cells. Dec 26, 2017; 9(12): 203-218
Published online Dec 26, 2017. doi: 10.4252/wjsc.v9.i12.203
Published online Dec 26, 2017. doi: 10.4252/wjsc.v9.i12.203
Figure 1 Schematic representation of primary surrogate endpoints grouped by categories.
LVEF: Left ventricle ejection fraction; LVEDV: Left ventricle end-diastolic volume; LVESV: Left ventricle end-systolic volume; MACE: Major adverse cardiac events; BNP: Brain natriuretic peptide; miRNAs: MicroRNAs; lncRNAs: Long non-coding RNAs.
- Citation: Dorobantu M, Popa-Fotea NM, Popa M, Rusu I, Micheu MM. Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease. World J Stem Cells 2017; 9(12): 203-218
- URL: https://www.wjgnet.com/1948-0210/full/v9/i12/203.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v9.i12.203